SCHEMBL5236407

SCHEMBL5236407

CCCCOc1c(N(C)C(=O)O)n(CC(C)(C)C)c(=O)c2ccc(OC)cc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.41
RORA P35398 1/20 0.41
RORC P51449 1/20 0.41
RORB Q92753 1/20 0.41
GRM2 Q14416 1/20 0.39
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CNR2 P34972 3/20 0.37
MAPK8 P45983 1/20 0.37
KCNA5 P22460 1/20 0.35
KCNH2 Q12809 1/20 0.35
PLA2G2A P14555 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
DPP4 P27487 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC6A5 Q9Y345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6698510 0.96 PGR (0.41) PGRRORARORCRORBGRM2
SCHEMBL5231052 0.94 PSEN1 (0.35) PGRRORARORCRORBMEN1
SCHEMBL5231956 0.92 CNR1 (0.35) PGRRORARORCRORBKDM4E
SCHEMBL5231641 0.92 HTT (0.36) KDM4EHSD17B10MEN1MAPTKMT2A
SCHEMBL5232660 0.92 PSEN1 (0.35) PGRRORARORCRORBPLA2G2A
SCHEMBL5235814 0.90 PSEN1 (0.33) PGRRORARORCRORBDPP4
SCHEMBL5233709 0.90 PSEN1 (0.35) PGRDPP4MEN1MAPTKMT2A
SCHEMBL5275963 0.89 RORA (0.37) PGRRORARORCRORBKDM4E
SCHEMBL5233891 0.89 RORA (0.37) RORARORCRORBCNR2DPP4
SCHEMBL5233040 0.89 DPP4 (0.35) RORCCNR2DPP4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed
EP-1355886-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed
WO-2002062764-A9 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-10-10 WO disclosed
WO-2002062764-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 PGR 4067/4885RORA 2682/4885RORC 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.